Numerous studies have demonstrated that NAFLD prevalence is markedly higher in insulin-resistant states, including obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome30,31. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.